Plus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
30 août 2023 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform...
Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
14 août 2023 16h05 HE
|
Plus Therapeutics Inc.
ReSPECT clinical trial data continues to demonstrate promise for treatment of leptomeningeal metastases and recurrent glioblastoma Received FDA approval to move into Phase 1/Part B of the ReSPECT-LM...
Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conference
11 août 2023 06h30 HE
|
Plus Therapeutics Inc.
Dose escalation trial demonstrates preliminary safety and efficacy results including median overall survival of 10 months for patients with leptomeningeal metastases FDA approves continuation to...
Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023
08 août 2023 16h05 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference
08 août 2023 11h22 HE
|
Plus Therapeutics Inc.
Trial investigators and company management to discuss latest data from the ReSPECT-LM leptomeningeal metastases clinical trial Webinar scheduled for Friday, August 11, 2023 at 8:00 a.m. ET AUSTIN,...
Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
03 août 2023 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operations
27 juil. 2023 16h05 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer Conference
27 juil. 2023 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit
13 juil. 2023 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual Meeting
29 juin 2023 07h00 HE
|
Plus Therapeutics Inc.
ReSPECT-GBM Phase 1 recurrent glioblastoma trial demonstrates safety and overall survival correlation with absorbed radiation dose ReSPECT-LM Phase 1/Part A leptomeningeal metastases trial...